Safety
RFK Jr. forces FDA to reconsider 12 unproven peptides after 2023 ban
In 2023, the FDA removed 19 peptides from the list of drugs that compounding pharmacies could produce, and in 2026 the FDA announced it will review whether to add back 7 of these peptides following pr
In 2023, the FDA removed 19 peptides from the list of drugs that compounding pharmacies could produce, and in 2026 the FDA announced it will review whether to add back 7 of these peptides following pressure from Health Secretary RFK Jr. The peptides under reconsideration, such as BPC-157, lack established safety and efficacy data and have been popular among wellness influencers despite having minimal research supporting their claimed benefits. RFK Jr. has argued the FDA acted illegally in its 2023 ban, though the agency originally cited documented safety concerns including immune reactions and potential organ damage.
Related
Source: Ars Technica | 2026-04-16